14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
Founder & Director, LPBI Group
Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
http://www.usaindiachamber.org
2021 summit- June 22. Marriott Cambridge, Massachusetts, USA
LPBI’s 2020 VISION
@pharma_BI
@AVIVA1950
#USAIC20
USAIC has created an ecosystem committed to driving a global dialogue on BioPharma & Healthcare innovation, attracting a diverse mix of senior industry professionals and catalyzing partnerships, new ideas, networks and regulatory reform. This unique platform creates mutually beneficial opportunities and relationships for the global Life Sciences & Healthcare industry.
14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition |
14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020,8 AM EST to 3-30 PM EST – Virtual Edition |
Chair and Master of Ceremonies (Emcee)– Dr. Andrew Plump, President of R&D, Takeda Pharmaceuticals
Timings are Eastern Standard Time (EST)
Time | Topic |
8 AM – 8-10 AM | Welcome address: Karun Rishi, President, USAIC
Opening comments: Dr Andrew Plump, President of R&D, Takeda Pharmaceuticals
|
8-10 AM – 8-50 AM | Panel Discussion- COVID-19: Where are we now? Where are we going?
Panelists:
Moderator: |
8-50 AM – 8-55 AM | Break + Polling |
8-55 AM – 9-10 AM | India Regulatory update
Dr. Mandeep Bhandari, Joint Secretary, Ministry of Health & Family Welfare, India
Dr. V G Somani, Drug Controller General of India, Central Drug Control Organization
Moderator:
|
9-10 AM – 9-15 AM | Break + Polling |
9-15 AM – 9-55 AM | Fireside Chat
Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. Strategies of Merck = “Medicine is for the People not for Profit”
Moderator:
|
9-55 AM – 10 AM | Break + Polling |
10 AM – 10-40 AM | India Innovation Landscape
Panelists:
Hari Bhartia, Founder & Co-Chairman, Jubilant Bhartia Group
Dr. K. Vijay Raghavan, Principal Scientific Advisor, Government of India Resources are necessary 30% from Industry vs Government and Academe with great students and labs Indian context – Personalized Medicine – Telemedicine and IT infrastructure allowing innovation in a 1Billion Population- sheer volume of quality professional Dr. Naresh Trehan, Chairman, Medanta – the Medicity
Moderator:
|
10-40 AM – 10-45 AM | Break + Polling |
10-45 AM – 11-25 AM | Panel Discussion- Oncology: Changing landscape- COVID learnings and the promise of new technologies
Panelists:
Dr. Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute
Dr. Philip Larsen, Global Head of Research, Bayer AG
Rehan Verjee, President, EMD Serono
Dr. Tony Ho, Head of Research and Development, CRISPR Therapeutics
Moderator:
|
11-25 AM – 11-30 AM | Break + Polling |
11-30 AM – 12-10 PM | Panel Discussion- Industry & Investment Outlook
Panelists:
Daphne Zohar, Founder & CEO, PureTech Health
Dr. Elias Zerhouni, Professor Emeritus, Johns Hopkins University
Dr. Stelios Papadopoulos, Chairman, Biogen
Moderator: President of Research & Development, Takeda Pharmaceuticals
Moderator Presenter: Dr. Michael Rosenblatt, CEO |
12-10 PM – 12-20 PM | Break + Polling |
12-20 PM – 1 PM | Panel Discussion- Rare Diseases: No longer forgotten; but more to be achieved
ROI is not there, regulatory requirements reduced, Registry Panelists:
Dr. Daniel Curran, Head of the Rare Diseases Therapeutic Area Unit, Takeda
Dr. David Meeker, Chairman & CEO , Rhythm Pharmaceuticals
Dr. John Orloff, Head of Research & Development, Alexion
Matt Wilsey, Co-Founder & Chairman, Grace Science Foundation
Moderator:
|
1 PM – 1-05 PM | Break + Polling |
1-05 PM – 1-50 PM | Fireside Chat
Dr. Roy Vagelos, Chairman of the Board, Regeneron Pharmaceuticals
Moderator:
|
1-50 PM – 1-55 PM | Break + Polling |
1-55 PM – 2-35 PM | Panel Discussion- Digital & Data Science in Healthcare: Pragmatic Insights from the Real-World
Panelists:
Arpa Garay, President, Global Pharmaceuticals, Commercial Analytics, Merck & Co.
Dr. Maya Said, Chief Executive Officer, Outcomes4Me
https://www.fda.gov/about-fda/oncology-center-excellence/project-patient-voice
Dr. Najat Khan, Chief Operating Officer, Janssen R&D Data Sciences, Johnson & Johnson
Nina Kjellson, General Partner, Canaan
Moderator:
|
2-35 PM – 2-40 PM | Break + Polling |
2-40 PM – 3-20 PM | Panel Discussion- R&D Strategies and Trends: Innovation – The Big I
Panelists:
Dr. David Reese, Executive Vice President, Research and Development, Amgen
Dr. Hal Barron, Chief Scientific Officer and President R&D, GlaxoSmithKline
Dr. Mathai Mammen, Global Head of Janssen Research & Development, Johnson & Johnson
Moderator: Moderator: Martin Mackay, Co-Founder, RallyBio
|
3-20 PM – 3-30 PM | Closing Remarks
|
Poll Questions for September 4
Polling Time (EST) | Polling Topic |
8-50 AM | COVID-19 PanelQuestion 1: What do you foresee as the most likely outcome of the race to develop a vaccine?
Question 2: What minimum criteria would you like to see for approval of COVID19 vaccines, assuming adequate efficacy?
|
9-10 AM | India Regulatory UpdateHow will MNCs respond to the recent regulatory changes for BioPharmas in India? They are _____ to run clinical trials there:
|
9-55 AM | Fireside Chat: Ken Frazier
The BioPharma industry this year has publicly committed itself to greater diversity. What specific measures do you expect to see?
|
10-40 AM | India Innovation LandscapeWhat is the most important step India could take to become a global leader in life sciences innovation?”
|
11-25 AM | Oncology PanelQuestion 1:
Changes in policy and reimbursement over the next five years will impact innovation in cancer therapeutics
Question 2: What therapeutic innovation do you think will have the biggest impact on cancer in the next five years?
|
12-10 PM | Industry & Investment Outlook PanelMore and more funding has been going into preclinical companies — do you expect this trend to continue?
R&D Strategies and Trends Panel COVID-19 has led to an unprecedented level of collaboration among stakeholders in the biopharma industry. Where do you expect to see the biggest increase in collaborations post-pandemic?
|
1 PM | Rare Diseases PanelWhat is the biggest barrier to access to Orphan drugs in low-income countries?
|
1-50 PM | Fireside Chat: Roy VagelosQuestion 1:
Will pharma’s reputation continue its positive trend or return to negative base line beyond the pandemic
Question 2: COVID-19 has put the spotlight on BioPharma as an essential player in the return to normalcy. What primary action do you think the industry needs to take to maintain a positive reputation beyond the pandemic?
|
2-35 PM | Digital & Data Sciences PanelWhere has COVID-19 had the biggest impact on your adoption and use of digital health technologies?
|
@@@@
In these unprecedented times due to COVID-19, USAIC is offering Free Registration for its annual summit. |
Click for free registration |
AGENDA & SPEAKERS
Chair and Master of Ceremonies (Emcee)– Dr. Andrew Plump, President of R&D, Takeda Pharmaceuticals
Summit Theme: “From N of One to N of a Billion”
- Moderated Fireside Chat- Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. and Stelios Papadopoulos, Chairman of the Board, Biogen
- Moderated Fireside Chat- Roy Vagelos, Chairman of the Board, Regeneron Pharmaceuticals and Mathai Mammen, Global Head of R&D, Janssen Pharmaceutical Companies of Johnson & Johnson
- Moderated Fireside Chat- K. VijayRaghavan, Principal Scientific Advisor, Government of India and Amitabh Kant, CEO, National Institution for Transforming India (NITI)
Panel Discussions:
- Covid-19: Where are we now? Where are we going?
- Oncology: A never ending tunnel?
- Rare Diseases: Breaking Barriers for a Healthy Brain
- Digital & Data Sciences: Leveraging data and digital to achieve healthcare solutions
- Industry & Investment Outlook
- R&D Strategies and Trends: Innovation – The Big I
Program and speakers subject to change*
SOURCE:
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.